Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form of slowness, rigidity, and tremors.

"The best medication for Parkinson's will come from Israel. It will be a hybrid medication, and the world's best hybrid ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

This pathway is heavily impacted by the loss of dopamine-producing neurons in Parkinson’s disease (PD). Targeting GPR6 ...

People with Parkinson’s disease are to benefit from cutting edge AI technology that allows neuroscientists to safely test medication and treatment on a ‘digital twin’ brain, thanks to a £1m funding ...

Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...

AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...

Although there is no cure, there are ways to relieve the tremors, stiffness, depression, anxiety, and memory problems caused ...

A Parkinson’s patient died after a 52-hour A&E wait meant he did not receive vital medication, an investigation has found. The 85-year-old man was sent to A&E after a routine hospital ...